Clinical Trials

Our clinical development program is focused on improving the lives of cancer patients utilizing innovative approaches either in monotherapy or in combination with existing therapies.

RESMAIN – Pivotal clinical study of resminostat as maintenance therapy in cutaneous T‑cell lymphoma

Our most advanced program evaluating resminostat in patients with cutaneous T‑cell lymphoma (CTCL) is at the pivotal stage of development. The RESMAIN study is being conducted in more than 50 centers in 11 European countries.

About the study

Press release

SENSITIZE – Phase Ib/II study of domatinostat (4SC-202) + checkpoint inhibitor pembrolizumab (Keytruda®, Merck) in melanoma

The SENSITIZE study will enroll 40 patients suffering from unresectable advanced-stage cutaneous melanoma who are refractory or non-responding to prior treatment with anti-PD-1 antibodies (checkpoint inhibitors). The study is being conducted at 6 certified skin cancer centers in Germany.

About the study

Overall survival benefit for resminostat in first-line liver cancer study subgroup

The addition of resminostat to the current standard of care – sorafenib – resulted in prolonged time till disease progression and a substantial benefit in median overall survival in a large subgroup of patients with a normal to high platelet count at study entry (50% of all patients in the study).

For these subgroup patients with higher baseline platelet levels, the risk of death during the study was reduced by approximately 40%, which represents a substantial benefit for patients with advanced HCC who have very few therapeutic alternatives.
Frank Hermann, M.D. | CDO

Patients in this subgroup treated with resminostat and sorafenib survived for 13.7 months as compared to 5.1 months for patients treated with sorafenib alone.

The Phase II trial evaluated the combination of sorafenib and resminostat versus sorafenib as first-line therapy in 170 patients with liver cancer (hepatocellular carcinoma, HCC) in Japan and Korea.

Press release

Share this page:

Follow us on: